美國Cambrex  www.cambrex.com 
美國Cambrex（BioWhittaker）公司作為美國最早的人體和動物細胞培養(yǎng)基的提供者，進入生物醫(yī)藥已有50年歷史。其細胞培養(yǎng)產(chǎn)品主要有細胞培養(yǎng)基和生長的普通培養(yǎng)基，無血清、無蛋白培養(yǎng)基，特殊細胞的專用培養(yǎng)基，培養(yǎng)用的血清、生長因子、試劑等。這些產(chǎn)品主要用在生物技術研究和生物制藥行業(yè)，如在藥物，癌癥治療，干細胞治療，遺傳治療，組織修復和移植等方面都有應用。另外在臨床癥斷實驗室，對有病歷的樣品進行病毒分離和鑒定方面也有應用。
最近隨著人體和動物正常細胞體系的最大供應商美國Clonetics公司和世界頂級瓊脂糖、凝膠生產(chǎn)者BMA（前FMC）公司的加盟。使Cambrex公司進入到細胞、細胞株供應培養(yǎng)和分子生物學領域。
Cambrex（BioWhittaker）公司鱟試劑內(nèi)毒素檢測產(chǎn)品被用在醫(yī)藥和醫(yī)學領域，作為質(zhì)量控制程序的一部分用來確保血管注射劑藥物和醫(yī)學儀器內(nèi)毒素含量對人體的安全性。鱟試劑內(nèi)毒素檢測比給動物注射進行檢測要更快，更精確，更經(jīng)濟實惠。
Cambrex公司所有產(chǎn)品的生產(chǎn)過程均符合美國GMP標準，并得到ISO9001國際認證，且獲得美國FDA生產(chǎn)許可。

Cambrex is a leading supplier of products and services for the Life Sciences industry. We have built comprehensive technology platforms for use in small molecule API and advanced pharmaceutical intermediate synthesis, including enhanced drug delivery. Cambrex has extensive experience developing process to manufacture drug substances for clients use in tox. studies, clinical studies and commercial supply - from grams to tons. Our broad range of services include route selection, process & analytical development, process optimization & scale-up, safety assessments, and product formulation, in addition to an extensive list of generic APIs. Cambrex’s offerings include Controlled Substances, High Potency/Cytotoxics, Highly Energetic Chemistries, Polymeric Drug Delivery, Biocatalysis/Biotransformation, Chiral Synthesis, Hydrogenation, and Nitrations.
 
We have R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record, and a strong expertise in various chemical technologies. We are committed to operating our facilities with the highest standards for regulatory, environmental, health, safety, and security guidelines. We have also adopted the Lean Six Sigma (LSS) Process to consistently deliver efficient, high quality, and cost competitive products with less time-to-market for our clients.
 
Our focus and goal is to provide solutions to large and small pharmaceutical companies with both established and emerging drug pipelines.